TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9240872

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Retinol-binding protein
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Prealbumin
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Vitamin A to retinol-binding protein ratio
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Micronutrient deficiency prevalence
Number of subjects: 467
Study: 7963729

Group type: EXPERIMENTAL
Intervention: HIV subunit vaccine (rgp120SF2) combined with MF59 adjuvant
Number of subjects: 42
Study: 2442512

Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Timolol (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Timolol and all beta-blocker/felodipine combinations
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Felodipine/beta-blocker combinations
Number of subjects: 10
Study: 28463904

Group type: EXPERIMENTAL
Intervention: Face-down positioning (FDP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nonsupine positioning (NSP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Gas fill
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Positioning (FDP or NSP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Gas-foveal contact
Number of subjects: 68
Study: 28167477

Group type: EXPERIMENTAL
Intervention: Entoban capsule 400mg every 8 hours for five days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Metronidazole tablets (400 mg) for 7‐10 days
Number of subjects: 150
Study: 25639660

Group type: EXPERIMENTAL
Intervention: Leucocyte telomere length
Number of subjects: 3275

Group type: COMPARATOR
Intervention: Rosuvastatin treatment
Number of subjects: 3275
Study: 23547489

Group type: EXPERIMENTAL
Intervention: Tongue cleaning with meridol HALITOSIS tooth & tongue gel (C)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Mechanical tongue cleaning alone (B)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (A)
Number of subjects: 54
Study: 21288078

Group type: EXPERIMENTAL
Intervention: Fidaxomicin (200 mg twice daily for 10 days)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Vancomycin (125 mg four times daily for 10 days)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 629

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 629
Study: 19463375

Group type: EXPERIMENTAL
Intervention: CYP2C19*1*1 carriers after a 600-mg dose
Number of subjects: 60

Group type: COMPARATOR
Intervention: CYP2C19*2 or *4 carriers after a 600-mg dose
Number of subjects: 60

Group type: COMPARATOR
Intervention: CYP2C19*17 carriers after a 600-mg dose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 or *4 carriers with higher loading dose at 4 h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 or *4 carriers with higher maintenance dose regimen
Number of subjects: 60
Study: 16650414

Group type: EXPERIMENTAL
Intervention: Inhibin A
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inhibin B
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Activin A
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Follicular fluid concentrations
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oocyte retrieval
Number of subjects: 35
Study: 14749149

Group type: EXPERIMENTAL
Intervention: BIAsp 30 + ROS (biphasic insulin aspart 30 plus rosiglitazone 4 mg once daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: GLIB + ROS (glibenclamide plus rosiglitazone 4 mg once daily)
Number of subjects: 49
Study: 10826396

Group type: EXPERIMENTAL
Intervention: Doxazosin (1 to 16 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 8858401

Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g/day for 3 weeks)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (3 g/day for 3 weeks)
Number of subjects: 6
Study: 1298591

Group type: EXPERIMENTAL
Intervention: Ridaura
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 6373165

Group type: EXPERIMENTAL
Intervention: Ceforanide 1 gm every twelve hours
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cefazolin 1 gm every eight hours
Number of subjects: 96
Study: 31787004

Group type: EXPERIMENTAL
Intervention: Close contact casting (CCC)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (surgery)
Number of subjects: 620
Study: 29439704

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) patterns
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: Isolated spurt (IS) and clustered spurt (CS) MVPA
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: Clustered sustained activity (CSA)
Number of subjects: 1131
Study: 24995700

Group type: EXPERIMENTAL
Intervention: Selective iron group (elemental iron 50 mg twice a day if diagnosed as anaemic)
Number of subjects: 2944

Group type: COMPARATOR
Intervention: Routine iron group (elemental iron 100 mg day(‐1) throughout pregnancy)
Number of subjects: 2944

Group type: EXPERIMENTAL
Intervention: Selective iron group
Number of subjects: 2944

Group type: COMPARATOR
Intervention: Routine iron group
Number of subjects: 2944
Study: 24604614

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: li‐rIPC
Number of subjects: 14
Study: 22762951

Group type: EXPERIMENTAL
Intervention: Peer change agent (PCA) identification and recruitment methodology based on social network analysis.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of friendship dynamics among truck-drivers.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Social network influences and risk reduction discussions.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pilot testing of PCA identification approach.
Number of subjects: 25
Study: 20170482

Group type: EXPERIMENTAL
Intervention: Intensive multi-factorial cardiovascular risk intervention
Number of subjects: 285

Group type: COMPARATOR
Intervention: Conventional care (according to current national guidelines)
Number of subjects: 285
Study: 17919489

Group type: EXPERIMENTAL
Intervention: HCV-specific CD8 T-cell response before treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HCV-specific CD8 T-cell responses during the first weeks of therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Late treatment phase T-cell responses
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baseline HCV-specific CD8 cell proliferative potential
Number of subjects: 32
Study: 15472652

Group type: EXPERIMENTAL
Intervention: Titanium fixation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resorbable fixation
Number of subjects: 60
Study: 11570617

Group type: EXPERIMENTAL
Intervention: Zafirlukast, 20 mg twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9924306

Group type: EXPERIMENTAL
Intervention: Prophylactic laser treatment (argon green laser, approximately 100 mild laser burns)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 7997324

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (topical prednisolone phosphate)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 2656266

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 23
Study: 5031656

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral propranolol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Other metabolic products of propranolol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Unidentified major metabolites of propranolol
Number of subjects: 14
Study: 31585796

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 500 mL of crystalloid solution
Number of subjects: 337

Group type: COMPARATOR
Intervention: No fluid bolus
Number of subjects: 337
Study: 28095397

Group type: EXPERIMENTAL
Intervention: Epirubicin, oxaliplatin and capecitabine (EOX)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oxaliplatin and capecitabine (OX)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Capecitabine alone (X)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Overall treatment utility (OTU)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Non-haematologic toxicity >grade 3
Number of subjects: 55
Study: 25769361

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban (60 mg once daily)
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban (30 mg once daily)
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin (dose adjusted to INR 2.0-3.0)
Number of subjects: 21105
Study: 22983832

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 120
Study: 21256626

Group type: EXPERIMENTAL
Intervention: Ketamine/Propofol
Number of subjects: 193

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 193
Study: 19996654

Group type: EXPERIMENTAL
Intervention: Daily oral EMP 10 mg/kg in 3 doses
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low-dose EMP 3 mg/kg once daily plus VP16 25 mg/m(2) once daily on days 1 through 14
Number of subjects: 56
Study: 16335163

Group type: EXPERIMENTAL
Intervention: Immediately loaded TiUnite implants
Number of subjects: 35

Group type: COMPARATOR
Intervention: Brånemark implants (control)
Number of subjects: 35
Study: 12077735

Group type: EXPERIMENTAL
Intervention: Standard therapy plus 1 mg hydroxocobalamin administered subcutaneously once per week after dialysis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard therapy (5 to 6 mg folic acid, 5 to 10 mg pyridoxine, and 6 to 10 microg oral vitamin B(12) per day)
Number of subjects: 24
Study: 9860110

Group type: EXPERIMENTAL
Intervention: Morphine 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Codeine 120 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8553795

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen infusion
Number of subjects: 18
Study: 2243253

Group type: EXPERIMENTAL
Intervention: Various randomization procedures (total randomization, Zelen-type, Efron-type, Simon-Pocock-type)
Number of subjects: 0
Study: 219964

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (13 courses of three infusions over 3 years, each infusion containing 12 mg/kg cyclophosphamide, 12 mg/kg 5‐fluorouracil, 0.5 mg/kg methotrexate, 0.1 mg/kg vinblastine)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (radical surgery only)
Number of subjects: 219
Study: 30336181

Group type: EXPERIMENTAL
Intervention: Adalimumab in combination with methotrexate (20 or 40 mg, according to body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate alone (up to 25 mg weekly)
Number of subjects: 0
Study: 28949162

Group type: EXPERIMENTAL
Intervention: Classical randomized algorithm for approximating the partition function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polynomial time algorithm for approximating free energy or ground energy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfect matching sum of a finite graph with positive edge weights
Number of subjects: 0
Study: 26036878

Group type: EXPERIMENTAL
Intervention: Papillary-like pancreaticojejunostomy
Number of subjects: 308

Group type: COMPARATOR
Intervention: Duct-to-mucosa pancreaticojejunostomy
Number of subjects: 308
Study: 23936144

Group type: EXPERIMENTAL
Intervention: Δ9‐tetrahydrocannabinol (THC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21751690

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (4 microg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 41
Study: 19433147

Group type: EXPERIMENTAL
Intervention: Increase physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduce stress through meditating
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-change control group
Number of subjects: 0
Study: 17143593

Group type: EXPERIMENTAL
Intervention: Pectoral stretching program (daily low-load, prolonged stretches)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no exercise advice)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups (stretch and control)
Number of subjects: 64
Study: 14730599

Group type: EXPERIMENTAL
Intervention: Combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine) plus prednisolone
Number of subjects: 195

Group type: COMPARATOR
Intervention: Single therapy with a DMARD with or without prednisolone
Number of subjects: 195
Study: 12575592

Group type: EXPERIMENTAL
Intervention: Antibiotics plus Chinese drugs combined treatment
Number of subjects: 153

Group type: COMPARATOR
Intervention: Simple antibiotics treatment
Number of subjects: 153
Study: 9456641

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate (Peridex) mouthrinses, twice daily for 6 days per week, supervised for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo mouthrinses, twice daily for 6 days per week, supervised for 3 months
Number of subjects: 60
Study: 8194639

Group type: EXPERIMENTAL
Intervention: Surgical lubricants
Number of subjects: 0
Study: 3285535

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) and prednisone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Azathioprine (Aza) and glucocorticoids
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Azathioprine (Aza)
Number of subjects: 108
Study: 29396738

Group type: EXPERIMENTAL
Intervention: Genetic-guided warfarin arm (GEN)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control arm (CTL)
Number of subjects: 180
Study: 26603056

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg twice daily plus Best Supportive Care (BSC)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Placebo plus Best Supportive Care (BSC)
Number of subjects: 764
Study: 23720394

Group type: EXPERIMENTAL
Intervention: MRI method for quantifying hepatic storage iron
Number of subjects: 26
Study: 24304838

Group type: EXPERIMENTAL
Intervention: Pedometer-alone group
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: Pedometer-plus-support group
Number of subjects: 993

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness assessment
Number of subjects: 993
Study: 20552099

Group type: COMPARATOR
Intervention: GIC (Ketac-Cem)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ACP-containing orthodontic cement (Aegis-Ortho)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GIC (Ketac-Cem) and ACP-containing cement (Aegis-Ortho)
Number of subjects: 60
Study: 19087842

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 6000
Study: 15850127

Group type: EXPERIMENTAL
Intervention: Locomotor-monitoring algorithm using LifeShirt system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study: 11880087

Group type: EXPERIMENTAL
Intervention: Water load
Number of subjects: 72

Group type: COMPARATOR
Intervention: No water load
Number of subjects: 72
Study: 10069783

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae IgG titers >/=1:16
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae IgG titers 1:32
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae IgG titers 1:64
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae IgG titers 1:128
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae IgG titers 1:256
Number of subjects: 343

Group type: COMPARATOR
Intervention: Chlamydia pneumoniae IgG seropositivity
Number of subjects: 343

Group type: COMPARATOR
Intervention: C-reactive protein concentration
Number of subjects: 343
Study: 7584746

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (ALB) 2.5 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (TERB) 0.25 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (saline injection)
Number of subjects: 83
Study: 2300680

Group type: EXPERIMENTAL
Intervention: Moclobemide (100, 200, and 300 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Deprenyl (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6932207

Group type: EXPERIMENTAL
Intervention: 25 mg PG F2α
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 50 mg PG F2α
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined prostaglandin-treated group (25 mg and 50 mg PG F2α)
Number of subjects: 90
Study: 30616650

Group type: EXPERIMENTAL
Intervention: Knowledge about availability of adolescent and youth friendly sexual and reproductive health services at health facilities
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Utilization of adolescent and youth friendly sexual and reproductive health services
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Educational status: being grade 9
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Educational status: being grade 11
Number of subjects: 144
Study: 27568072

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (800mg calcium and 400IU vitamin D daily, n=8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (n=9)
Number of subjects: 17
Study: 26525550

Group type: EXPERIMENTAL
Intervention: Fast-track surgery combined with Chinese medicine treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 72
Study: 23351578

Group type: EXPERIMENTAL
Intervention: Wax-matrix extended-release niacin (WMER) 1500 mg/d
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Inositol hexanicotinate (IHN) 1500 mg/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 21327538

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18801639

Group type: EXPERIMENTAL
Intervention: Self-help treatment (book and 6 weeks of DVD or videotape)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 247
Study: 17439514

Group type: EXPERIMENTAL
Intervention: Polydimethylsiloxane elastomer
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 44
Study: 14671645

Group type: EXPERIMENTAL
Intervention: Pegylated rIFN-alpha2b (6 microg/kg/week)
Number of subjects: 344

Group type: COMPARATOR
Intervention: rIFN-alpha2b (5 million International Units/m2/day)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Pegylated rIFN-alpha2b (6 microg/kg/week) among patients with HCT >33%
Number of subjects: 344

Group type: COMPARATOR
Intervention: rIFN-alpha2b (5 million International Units/m2/day) among patients with HCT >33%
Number of subjects: 344
Study: 11403176

Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg three times per day starting the day before radiation therapy)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Radiotherapy without pilocarpine (Control group)
Number of subjects: 49
Study: 10888995

Group type: EXPERIMENTAL
Intervention: Hot dissection tonsillectomy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 54
Study: 8933126

Group type: EXPERIMENTAL
Intervention: 15 g of raw ginger root daily for two weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 40 g of cooked stem ginger daily for two weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1579513

Group type: EXPERIMENTAL
Intervention: Immunofluorescent method (IFL)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Micro-ELISA method
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both IFL and ELISA methods
Number of subjects: 16
Study: 4064546

Group type: EXPERIMENTAL
Intervention: 50.0 Gy in 20 daily fractions
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 52.5 Gy in 20 daily fractions
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 57.5 Gy in 20 daily fractions
Number of subjects: 94
Study: 30032505

Group type: EXPERIMENTAL
Intervention: 200 ml 12.5% CHO
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 300 ml 12.5% CHO
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 400 ml 12.5% CHO
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 500 ml 12.5% CHO
Number of subjects: 100
Study: 26325531

Group type: EXPERIMENTAL
Intervention: Triple-site ventricular stimulation (TRIV)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional CRT
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: TRIV
Number of subjects: 76
Study: 24332514

Group type: EXPERIMENTAL
Intervention: Oral ibandronic acid 50 mg daily
Number of subjects: 705

Group type: COMPARATOR
Intervention: Intravenous zoledronic acid 4 mg every 3-4 weeks
Number of subjects: 705
Study: 22290638

Group type: EXPERIMENTAL
Intervention: Diagnosis-mixed psychoeducational (PE)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-specific intervention control group
Number of subjects: 82